Ginkgo Bioworks Holdings, Inc.
DNA
$10.76
-$0.43-3.84%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 230.82M | 237.42M | 227.04M | 217.95M | 184.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 230.82M | 237.42M | 227.04M | 217.95M | 184.34M |
| Cost of Revenue | 48.49M | 47.39M | 44.55M | 41.54M | 36.46M |
| Gross Profit | 182.32M | 190.02M | 182.50M | 176.41M | 147.88M |
| SG&A Expenses | 196.60M | 219.61M | 240.85M | 253.94M | 283.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 4.29M | 4.29M | -2.02M | -2.02M | -2.02M |
| Total Operating Expenses | 527.06M | 629.81M | 707.44M | 758.19M | 862.50M |
| Operating Income | -296.24M | -392.40M | -480.40M | -540.24M | -678.16M |
| Income Before Tax | -316.09M | -472.50M | -547.51M | -651.54M | -897.68M |
| Income Tax Expenses | -895.00K | -422.00K | -479.00K | -352.00K | 1.00K |
| Earnings from Continuing Operations | -315.19 | -472.08 | -547.03 | -651.19 | -897.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -315.19M | -472.08M | -547.03M | -651.19M | -897.68M |
| EBIT | -296.24M | -392.40M | -480.40M | -540.24M | -678.16M |
| EBITDA | -232.26M | -326.88M | -417.38M | -480.03M | -614.07M |
| EPS Basic | -5.85 | -8.98 | -10.62 | -12.90 | -18.03 |
| Normalized Basic EPS | -3.06 | -4.19 | -5.28 | -5.99 | -7.70 |
| EPS Diluted | -5.86 | -8.99 | -10.63 | -12.92 | -18.05 |
| Normalized Diluted EPS | -3.06 | -4.19 | -5.28 | -5.99 | -7.70 |
| Average Basic Shares Outstanding | 215.16M | 211.67M | 207.54M | 203.16M | 199.69M |
| Average Diluted Shares Outstanding | 215.16M | 211.68M | 207.57M | 203.23M | 199.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |